Syracuse

SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data

Archive ouverte

Nguyen, Dung | Simmonds, Peter | Steenhuis, Maurice | Wouters, Elise | Desmecht, Daniel | Garigliany, Mutien | Romano, Marta | Barbezange, Cyril | Maes, Piet | van Holm, Bram | Mendoza, Joaquín | Oyonarte, Salvador | Fomsgaard, Anders | Lassaunière, Ria | Zusinaite, Eva | Resman Rus, Katarina | Avšič-Županc, Tatjana | Reimerink, Johan Hj | Brouwer, Fiona | Hoogerwerf, Marieke | Reusken, Chantal Bem | Grodeland, Gunnveig | Le Cam, Sophie | Gallian, Pierre | Amroun, Abdennour | Brisbarre, Nadège | Martinaud, Christophe | Leparc Goffart, Isabelle | Schrezenmeier, Hubert | Feys, Hendrik | van Der Schoot, C Ellen | Harvala, Heli

Edité par CCSD ; European Centre for Disease Prevention and Control -

International audience. We compared the performance of SARS-CoV-2 neutralising antibody testing between 12 European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-fold differences between laboratories when blind-testing 15 plasma samples. Calibration of titres in relation to the reference reagent and standard curve obtained by testing a dilution series reduced the inter-laboratory variability ca 10-fold. The harmonisation of neutralising antibody quantification is a vital step towards determining the protective and therapeutic levels of neutralising antibodies.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion